WO2007149404A2 - Stent auto-nettoyant - Google Patents

Stent auto-nettoyant Download PDF

Info

Publication number
WO2007149404A2
WO2007149404A2 PCT/US2007/014214 US2007014214W WO2007149404A2 WO 2007149404 A2 WO2007149404 A2 WO 2007149404A2 US 2007014214 W US2007014214 W US 2007014214W WO 2007149404 A2 WO2007149404 A2 WO 2007149404A2
Authority
WO
WIPO (PCT)
Prior art keywords
self
stent
weighted object
tubular body
elongated tubular
Prior art date
Application number
PCT/US2007/014214
Other languages
English (en)
Other versions
WO2007149404A3 (fr
Inventor
Matthew P. Carter
Brian K. Jones
Original Assignee
Wilson-Cook Medical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wilson-Cook Medical Inc. filed Critical Wilson-Cook Medical Inc.
Priority to AU2007261513A priority Critical patent/AU2007261513B2/en
Priority to AT07809644T priority patent/ATE522190T1/de
Priority to CA2659735A priority patent/CA2659735C/fr
Priority to EP07809644A priority patent/EP2032089B1/fr
Priority to JP2009516532A priority patent/JP2009540926A/ja
Publication of WO2007149404A2 publication Critical patent/WO2007149404A2/fr
Publication of WO2007149404A3 publication Critical patent/WO2007149404A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/32—Surgical cutting instruments
    • A61B2017/320004—Surgical cutting instruments abrasive
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/32—Surgical cutting instruments
    • A61B2017/320004—Surgical cutting instruments abrasive
    • A61B2017/320012—Brushes

Definitions

  • the present invention relates to implantable medical devices. More particularly, the invention relates to stents, including stents adapted for use in the biliary tract.
  • Stents are frequently used to enlarge, dilate, or maintain the patency of narrowed body lumens.
  • Non -expandable stents are typically made from plastics and contain a lumen extending throughout.
  • Implantation of biliary stent structures provides treatment for various conditions, such as obstructive jaundice.
  • Biliary stenting treatment approaches can be used to provide short-term treatment of conditions such as biliary fistulae or giant common duct stones.
  • Biliary stents may be implanted to treat chronic conditions such as postoperative biliary stricture, primary sclerosing cholangitis and chronic pancreatitis.
  • a biliary stent can be made in the form of a polymer tube that can be advanced on a delivery catheter through an endoscope and into the bile duct where it is deployed.
  • the tubular stent is selected to be sufficiently strong to resist collapse to maintain an open lumen through which digestive liquids can flow into the digestive tract.
  • a stent is that it be longitudinally flexible to be advanced along a path that may include sharp bends.
  • the stent also should maintain its intended position within the bile duct without migrating from that position.
  • Cumulative matter is material traversing the stent that if undisturbed, would otherwise accumulate on the passageway surfaces to reduce the diameter of the flow path and could eventually clog the stent.
  • Cumulative matter includes, but is not limited to biofilm, bacterial growth, and sludge deposition. Thus, cumulative matter can prevent further bodily fluid from passing therethrough.
  • a biliary stent can become occluded within a bile duct, as cumulative material, such as an encrustation of amorphous biological material and bacteria ("sludge”), accumulates on the surface of the stent gradually obstructing the lumen of the stent.
  • Biliary sludge is an amorphous substance often containing crystals of calcium bilirubinate and calcium palimitate, along with significant quantities of various proteins and bacteria. Sludge can deposit rapidly upon implantation in the presence of bacteria. For example, bacteria can adhere to plastic stent surfaces through pili or through production of a mucopolysaccharide coating. Bacterial adhesion to the surface of a stent lumen surface can lead to occlusion of the stent lumen as the bacteria multiply within a glycocalyx matrix of the sludge to form a biofilm over the sludge within the lumen of an implanted drainage stent. The biofilm can provide a physical barrier protecting encased bacteria from antibiotics.
  • an implanted biliary stent lumen can become blocked, thereby restricting or blocking bile flow through the biliary stent.
  • a patient can develop symptoms of recurrent biliary obstruction due to restricted or blocked bile flow through an implanted biliary stent, which can be complicated by cholangitis and sepsis.
  • 0007] Often, such conditions are treated by antibiotics and/or endoscopic replacement of an obstructed biliary stent.
  • biliary stents need replacing every three months. Replacement procedures cause medical risk and financial strain to the patient.
  • a self-cleaning stent in a first aspect of the present invention, includes an elongated tubular body having a first portion, a second portion, and a lumen extending throughout.
  • the device also includes a weighted object that is movably disposed about the elongated tubular body.
  • the weighted object is configured to dislodge cumulative matter disposed within the elongated tubular body.
  • the device further includes a securing mechanism configured for securing the weighted object about the elongated tubular body.
  • a self-cleaning stent is provided in a second aspect of the present invention.
  • the device includes an elongated tubular body having a first portion, a second portion, a lumen extending throughout, and at least one side drainage port.
  • the device further includes at least one weighted object moveably disposed within the elongated tubular body, wherein the weighted object is configured to dislodge cumulative matter disposed within the elongated tubular body.
  • the device further includes a securing mechanism for maintaining the weighted object within the elongated tubular body.
  • a method for preventing occlusion of a stent includes providing a self-cleaning stent having an elongated tubular body and at least one weighted object moveably disposed about the elongated tubular body.
  • the weighted object is configured to dislodge cumulative matter disposed within the elongated tubular body in response to a force selected from the group consisting of patient movement, fluid flow, and changes in the gravitational force.
  • the method further includes implanting the self-cleaning stent into a bodily lumen of a patient.
  • a self-cleaning stent in addition, includes an elongated tubular body having a first portion, a second portion, and a lumen extending throughout, a weighted object that is movably disposed about the elongated tubular body, wherein the weighted object is configured to at least partially dislodge cumulative matter deposited within the elongated tubular body to facilitate maintenance of a flow path therethrough, and a securing mechanism configured for securing the weighted object about the elongated tubular body.
  • a self-cleaning stent is provided.
  • the device includes an elongated tubular body having a first portion, a second portion, a lumen extending throughout, and at least one side drainage port, at least one weighted object moveably disposed within the elongated tubular body, wherein the weighted object is configured to at least partially dislodge cumulative matter deposited within the elongated tubular body to facilitate maintenance of a flow path therethrough, and a securing mechanism for maintaining the weighted object within the elongated tubular body.
  • a method for preventing occlusion of a stent includes providing a self-cleaning stent having an elongated tubular body and at least one weighted object moveably disposed about the elongated tubular body, wherein the weighted object is configured to at least partially dislodge cumulative matter deposited within the elongated tubular body to facilitate maintenance of a flow path therethrough in response to a force selected from the group consisting of patient movement, fluid flow, and changes in the gravitational force and implanting the self-cleaning stent into a bodily lumen of a patient.
  • FIG. 1 is a partial cross sectional perspective view of a self-cleaning stent
  • Fig. 2 is an end view of the self-cleaning stent depicted in Fig. 1;
  • Fig. 3 is a partial cross sectional perspective view of another self- cleaning stent;
  • Fig. 4 is an end view of the self-cleaning stent depicted in Fig. 3;
  • Fig. 5 is a partial cross sectional perspective view of another self- cleaning stent;
  • FIG. 6 is a partial cross sectional perspective view of another self- cleaning stent
  • Fig. 7 is a partial cross sectional perspective view of another self- cleaning stent.
  • Fig. 8 is a partial cross sectional perspective view of another self- cleaning stent.
  • the exemplary embodiments disclosed herein provide self-cleaning stents that are able to at least inhibit long term adherence of cumulative matter to the interior of the stent so that the amount of time the stent can reside within a patient before needing to be replaced is extended.
  • the present invention is not limited to non-expandable stents; it is contemplated that self-expanding stents can also be improved by the inventive concepts disclosed herein.
  • the present invention is not limited to use within any particular part of the body or for use with humans.
  • Fig. 1 is a partial cross sectional perspective view of an illustrative embodiment of a self-cleaning biliary stent.
  • Self-cleaning stent 10 comprises a first portion 11, second portion 12, and a lumen 17 extending throughout.
  • Walls 18 of self-cleaning stent 10 are about .020 inches thick and the outer diameter of self-cleaning stent 10 is about 3-10 French. However, other sizes are contemplated depending on the needs of the patient, the size of weighted object 13, and the diameter of the body lumen in which self-cleaning stent 10 will dwell.
  • Side drainage ports 15 contained within walls 18 allow for additional fluid to pass therethrough.
  • Side drainage ports 15 can be configured in such a way that side drainage ports 15 do not come in contact with tissue; e.g. side drainage ports 15 can be placed near second portion 12 or first portion 11 of walls 18, wherein such portion of walls 18 would not come in contact with any portion of the bodily tissue wherein self-cleaning stent 10 dwells.
  • second portion 12 configured with side drainage ports 15 can be extended out into the duodenum such that side drainage ports 15 do not contact and therefore, are not blocked by, any tissue.
  • weighted object 13 Contained within self-cleaning stent 10 is weighted object 13 that is free to move about lumen 17. Weighted object 13 is made from ceramic, stainless steel, or gold.
  • Weighted object 13 moves longitudinally within lumen 17 in response to patient movement, fluid flow, and/or changes in the gravitational force. As weighted object 13 moves, it contacts inner surface 101 of walls 18 so as to dislodge any cumulative matter attached thereto. The cumulative matter then exits through first portion 11 or second portion 12 of self-cleaning stent 10. Cumulative matter can also exit via side drainage ports 15. Weighted object 13 is preferably 5-10 grams; however, other masses are contemplated. Weighted object
  • weighted object 13 should be sufficiently sized and shaped such that it does not completely obstruct fluid flow and such that it is able to move about lumen 17 without causing stent 10 to become dislodged from its dwelling place.
  • the shape of weighted object 13 is not limited to having a circular-shape; other shapes are contemplated including, but not limited to, those having a square-shape, rectangular-shape, cylindrical-shape, or triangular-shape. Additionally, weighted object 13 may have additional materials or coatings attached thereto to aid in the removal of cumulative matter.
  • Self-cleaning stent 10 also comprises two end cap securing mechanisms
  • End caps 14 (also shown in Fig. 2) that are extruded as part of walls 18, although it is contemplated that end caps 14 could be separate pieces fixedly attached to first portion 11 and second portion 12 of self-cleaning stent 10. Additionally, it is contemplated that end caps 14 could reside within walls 18 of self-cleaning stent 10. End caps 14 prevent the escape of weighted object 13 from lumen 17 and have openings 16 to allow fluid to pass therethrough. End cap 14 is not limited to having a cross-shape, but may include other configurations that are able to prevent the escape of weighted object 13 from lumen 17 and allow fluid to pass therethrough.
  • Walls 18 can be formed from any suitable biocompatible and biostable material. Walls 18 are preferably resiliently compliant enough to readily conform to the curvature of the duct in which it is to be placed, while having sufficient "hoop" strength to retain its form within the duct. Walls 18 of self-cleaning stent 10 are preferably made from a medium density biocompatible polyethylene, although other materials are contemplated, including but not limited to polyurethane, polytetrafluoroethylene (PTFE), stainless steel, and Nitinol. In one aspect, walls 18 are formed from a polyolefin such as a metallocene catalyzed polyethylene, polypropylene, polybutylene or copolymers thereof.
  • a polyolefin such as a metallocene catalyzed polyethylene, polypropylene, polybutylene or copolymers thereof.
  • suitable materials for walls 18 include polyurethane (such as a material commercially available from Dow Corning under the tradename PELLETHANE); a silicone rubber (such as a material commercially available from Dow Corning under the tradename SILASTIC); a polyetheretherketone (such as a material commercially available from Victrex under the tradename PEEK); vinyl aromatic polymers such as polystyrene; vinyl aromatic copolymers such as styrene-isobutylene copolymers and butadiene-styrene copolymers; ethyl enic copolymers such as ethylene vinyl acetate (EVA), ethylene- methacrylic acid and ethylene- acrylic acid copolymers where some of the acid groups have been neutralized with either zinc or sodium ions (commonly known as ionomers); polyacetals; chloropolymers such as polyvinylchloride (PVC); polyesters such as polyethyleneterephthalate (PET); polyester-ethers; polyamide
  • the surface of self-cleaning stent 10 can be coated with a polymer.
  • Walls 18 are illustrated as having a polymer coating on both its outer surface 19 and its inner surface 101.
  • Weighted object 13 is illustrated as having a polymer coating on its outer surface 102.
  • the polymer coating on outer surface 19, 102 and inner surface 101 can be a biocompatible polymer, including but not limited to PTFE.
  • Polymer coating can also comprise a hydrophilic polymer selected from the group comprising polyacrylate, copolymers comprising acrylic acid, polymethacrylate, polyacrylamide, poly(vinyl alcohol), poly(ethylene oxide), poly(ethylene imine), carboxymethylcellulose, methylcellulose, poly(acrylamide sulphonic acid), polyacrylonitrile, poly(vinyl pyrrolidone), agar, dextran, dextrin, carrageenan, xanthan, and guar.
  • the hydrophilic polymers can also include ionizable groups such as acid groups, e.g., carboxylic, sulphonic or nitric groups.
  • the hydrophilic polymers may be cross-linked through a suitable cross-binding compound. The cross-binder actually-used depends on the polymer system: if the polymer system is polymerized as a free radical polymerization, a preferred cross- binder comprises two or three unsaturated double bonds.
  • the polymer coating on inner surface 101 and outer surface 19, 102 can also be loaded with a variety of bioactive agents.
  • the bioactive agent preferably includes one or more antimicrobial agents.
  • antimicrobial agent refers to a bioactive agent effective in the inhibition of, prevention of or protection against microorganisms such as bacteria, microbes, fungi, viruses, spores, yeasts, molds and others generally associated with infections such as those contracted from the use of the medical articles described herein.
  • the antimicrobial agents include antibiotic agents and antifungal agents.
  • Antibiotic agents may include cephalosporins, clindamycin, chloramphenicol, carbapenems, penicillins, monobactams, quinolones, tetracycline, macrolides, sulfa antibiotics, trimethoprim, fusidic acid and aminoglycosides.
  • Antifungal agents may include amphotericin B, azoles, flucytosine, cilofungin and nikkomycin Z.
  • antibiotic agents include: ciprofloxacin, doxycycline, amoxicillin, metronidazole, norfloxacin (optionally in combination with ursodeoxycholic acid), ciftazidime, and cefoxitin.
  • suitable antibiotic agents include rifampin, minocycline, novobiocin and combinations thereof discussed in U.S. Patent No. 5,217,493 (Raad et al.), which is incorporated herein by reference in its entirety.
  • Rifampin is a semisynthetic derivative of rifamycin B, a macrocyclic antibiotic compound produced by the mold Streptomyces mediterranic.
  • Minocycline is believed to inhibit bacterial DNA-dependent RNA polymerase activity and is bactericidal in nature. Rifampin is available in the United States from Merrill Dow Pharmaceuticals, Cincinnati, Ohio.
  • Minocycline is a semisynthetic antibiotic derived from tetracycline. It is primarily bacteriostatic and is believed to exert an antimicrobial effect by inhibiting protein synthesis.
  • Minocycline is commercially available as the hydrochloride salt which occurs as a yellow, crystalline powder and is soluble in water and slightly soluble in alcohol. Minocycline is available from Lederle Laboratories Division, American Cyanamid Company, Pearl River, N. Y.
  • Novobiocin is an antibiotic obtained from cultures of Streptomyces niveus or S.
  • Novobiocin is usually bacteriostatic in action and is believed to interfere with bacterial cell wall synthesis and inhibit bacterial protein and nucleic acid synthesis. Novobiocin also appears to affect stability of the cell membrane by complexing with magnesium. Novobiocin is available from The Upjohn Company, Kalamazoo, Michigan.
  • the polymer coating is preferably capable of releasing the bioactive agent into the body at a predetermined time and at a predetermined rate.
  • Such polymeric coatings include drug-eluting matrix materials described in U.S. Patent Nos. 5,380,299, 6,530,951 , 6,774,278 and U.S. Patent Application Serial Nos. 10/218,305, 10/223,415, 10/410,587, 10/000,659, and 10/618,977 all of which are incorporated in their entirety herein by reference.
  • polymer coatings can be coated on outer surface 19, 102 and inner surface 101.
  • the polymer coating on outer surface 19 can include any polymer coating commonly known to those skilled in the art to help reduce tissue irritation incurred as a result of self-cleaning stent 10 being in contact with a passageway of the patient for a prolonged period of time.
  • the polymer coating on inner surface 101 and outer surface 102 can also include any coating commonly known to those skilled in the art to further help prevent clogging of self-cleaning stent 10.
  • inner surface 101 and outer surface 19, 102 of self- cleaning stent 10 can be composed from a biodegradable polymer that gradually bioerodes with time.
  • Biodegradable polymers may include rigid dissolvable polymers such as poly(lactid acid), poly(glycolic acid), and poly-epsilon-capro- lactone, or combinations thereof. Other rigid dissolvable polymers will be apparent to those of ordinary skill in the art.
  • Suitable biodegradable polymers may be selected from the group consisting of: a hydrogel, an elastin-like peptide, a polyhydroxyalkanoates (PHA), polyhydroxybutyrate compounds, and co-polymers and mixtures thereof.
  • the biodegradable material can be selected and varied based on various design criteria.
  • the biodegradable material preferably comprises one or more hydrolyzable chemical bonds, such as an ester, a desired degree of crosslinking, a degradation mechanism with minimal heterogeneous degradation, and nontoxic monomers.
  • the biodegradable material is preferably a polyhydroxyalkanoate compound, a hydrogel, poly(glycerol-sebacate) or an elastin-like peptide.
  • the biodegradable material comprises a poly- ⁇ -hydroxy acid, such as polylactic acid (PLA).
  • PLA can be a mixture of enantiomers typically referred to as poly-D,L-lactic acid.
  • the biodegradable material is poly-L(+)-lactic acid (PLLA) or poly-D(-)-lactic acid (PDLA), which differ from each other in their rate of biodegradation.
  • PLLA is semicrystalline.
  • PDLA is amorphous, which can promote the homogeneous dispersion of an active species.
  • PLA poly-L(+)-lactic acid
  • PDLA poly-D(-)-lactic acid
  • Self-cleaning stent 10 comprising a drug-releasing coating may be formed by any suitable process conventionally used to shape polymeric materials such as thermoplastic and elastomeric materials. Shaping processes can include, but not limited to, extrusion including coextrusion, molding, calendaring, casting and solvent coating. Preferred shaping processes include extrusion and coextrusion processes. For example, a biodegradable coating polymer mixed with a drug may be applied to inner surface 101 of self-cleaning stent 10 by applying a solvent solution or liquid dispersion of a biodegradable polymer onto a surface of the walls 18 followed by removing the solvent or liquid dispersing agent, e.g., by evaporation.
  • a biodegradable coating polymer mixed with a drug may be applied to inner surface 101 of self-cleaning stent 10 by applying a solvent solution or liquid dispersion of a biodegradable polymer onto a surface of the walls 18 followed by removing the solvent or liquid dispersing agent, e.g., by
  • Such a solution or dispersion of the biodegradable polymer may be applied by contacting a surface of the support member with the solution or dispersion by, for example, dipping or spraying.
  • the biodegradable coating may be applied by spraying a solution of a biodegradable polymer onto walls 18 within the lumen of self-cleaning stent 10.
  • a coated self- cleaning stent 10 can be formed by applying a polymer to the exterior surface of a biodegradable coating to form a multilayer medical device.
  • a solution of a biostable polymer can be applied to the external surface of a tube of the biodegradable coating and dried in place to form self-cleaning stent 10.
  • each of the multiple layers may be solvent cast.
  • the second layer is cast from a solvent that does not dissolve the already-cast layer.
  • a polyurethane used to form self-cleaning stent 10 may be dissolved in dimethylformamide, while PLA used to form a biodegradable coating may be dissolved in dichloromethane.
  • the second solution may be spread on the first layer once dry, and the solvent evaporated off. The resulting multi-layers have a strong bond between the layers.
  • Biodeposition-reducing bioactive agents can be selected to withstand the extrusion temperature.
  • a bioactive agent may be included within, or mixed with, the polymer prior to extrusion. Extrusion of the film allows inclusion of a drug or agent that can withstand the extrusion temperatures.
  • the antimicrobial agents described in U.S. patent application US2005/0008763A1 are compatible with this manufacturing technique, which is incorporated herein by reference in its entirety.
  • the bioactive agent preferably does not materially interfere with the physical or chemical properties of the biodegradable material in which it is included.
  • the bioactive agent and the biodegradable material may be preformed using any of the conventional devices known in the art for such purposes.
  • a polymer melt may be formed by heating the various agents, which can then be mixed to form a homogenous mixture.
  • a common way of doing so is to apply mechanical shear to a mixture of the matrix polymer and additives.
  • Devices in which the biodegradable material and the bioactive(s) may be mixed in this fashion include, but are not limited to, devices such as a single screw extruder, a twin screw extruder, a banbury mixer, a high-speed mixer, and a ross kettle.
  • the biodegradable coating is adhered to self-cleaning stent 10 without a bioactive agent, and the bioactive agent may be subsequently absorbed into the biodegradable coating after the formation of the device.
  • the biodegradable coating can be contacted with a solution of the bioactive agent within the drainage lumen of self-cleaning stent 10.
  • the effective concentration of the bioactive agent within the solution can range from about 1 to 10 ⁇ g/ml for minocycline, preferably about 2 ⁇ g/ml; 1 to 10 ⁇ g/ml for rifampin, preferably about 2 ⁇ g/ml; and 1 to 10 ⁇ g/ml for novobiocin, preferably about 2 ⁇ g/ml.
  • the solution is preferably composed of sterile water or sterile normal saline solutions.
  • Fig. 3 depicts an alternate illustrative embodiment of a self-cleaning stent.
  • Self-cleaning stent 20 comprises end cap securing mechanisms 24 (also shown in Fig. 4) that are extruded as part of walls 18, although it is contemplated that end caps 24 could be separate pieces fixedly attached to first portion 21 and second portion 22 of self-cleaning stent 20. Additionally, it is contemplated that end caps 24 could reside within walls 18 of self-cleaning stent 20. End caps 24 prevent the escape of weighted objects 26 and provide openings 25 to allow fluid to pass through lumen 23.
  • End cap 24 is not limited to having a diagonal shape, but may include other configurations that are able to prevent the escape of weighted objects 26 from lumen 23 and allow fluid to pass therethrough.
  • End cap 24 Within lumen 23 are multiple weighted objects 26 having differing sizes. Weighted objects 26 are able to move about freely within lumen 23. In response to patient movement, fluid flow, and/or changes in the gravitational force, weighted objects 26 move and come in contact with each other and with inner surface 101 of walls 18 and dislodge cumulative matter attached thereto.
  • weighted objects 26 can have a variety of different shapes, including but not limited to a square-shape, rectangular-shape, cylindrical-shape, or triangular-shape. Additionally, a particular weighted object 26 may have a shape, size, and coating 102 different from that of another weighted object 26. Additionally, weighted objects 26 may have additional materials or coatings attached thereto to aid in the removal of cumulative matter.
  • Fig. 5 depicts another illustrative embodiment of a self-cleaning biliary stent.
  • Weighted object 36 is connected via a line 35 to first portion 31 via a connection point securing mechanism 34.
  • Line 35 is a stainless steel braided cable.
  • Line 35 limits the distance to which weighted object 36 can travel in the direction of second portion 32; therefore, second portion 32 of self-cleaning stent 30 need not be partially occluded.
  • line 35 can be connected to weighted object 36 such that it offsets the center of gravity of weighted object 36.
  • weighted object 36 can be configured in such a way that the center of gravity is not located directly at the center of weighted object 36; thus, weighted object 36 would be more likely to move about lumen 33.
  • Weighted object 36 moves within lumen 33 of self-cleaning stent 30 in response to patient movement, fluid flow, and/or changes in the gravitational force. As weighted object 36 moves about lumen 33, it contacts inner surface 101 of walls 18 so as to dislodge cumulative matter attached thereto.
  • the shape of weighted object 36 is not limited to having a cylindrical shape. Other shapes are contemplated including, but not limited to, those having a square-shape, rectangular-shape, circular-shape, or triangular-shape. Additionally, weighted object 36 may have additional materials or coatings attached thereto to aid in the removal of cumulative matter.
  • line 35 can be configured such that weighted object 36 extends out from stent 30 so as to act as a pendulum. As such, line 35 would scrape against inner surface 101 of walls 18 dislodging cumulative matter attached thereto.
  • Such a configuration may be beneficial when self-cleaning stent 30 is used in the duodenum, wherein second portion 32 is configured to extend into the duodenum with weighted object 36 acting as a pendulum hanging in the duodenum.
  • Fig. 6 depicts another illustrative embodiment of a self-cleaning stent.
  • Connection point securing mechanisms 43 are located at first portion 41 and second portion 42 of self-cleaning stent 40. Attached to connection points 43 is a line 44 that passes through lumen 48 of weighted object 46 such that weighted object 46 freely slides along line 44. Weighted object 46 moves within lumen 45 of self-cleaning stent 40 in response to patient movement, fluid flow, and/or changes in the gravitational force.
  • Connection points 43 restrict the movement of weighted object 46 to within lumen 45, however, line 44 has slack so that weighted object 46 is able to contact inner surface 101 of walls 18.
  • weighted object 46 moves about lumen 45, bristles 47 contact inner surface 101 of walls 18 so as to dislodge cumulative matter attached thereto.
  • the shape of weighted object 46 is not limited to having a circular-shape; other shapes are contemplated including, but not limited to, those having a rectangular-shape, square-shape, cylindrical-shape, or triangular-shape.
  • weighted object 46 is not limited to having triangular-shaped bristles 47, other shapes are contemplated including, but not limited to, those having a square-shape, cylindrical-shape, rectangular-shaped, or circular- shape.
  • weighted objects having the same or different sizes, shapes, and coatings 102 could be added along line 44. Additionally, it is further contemplated that more than one sliding line 44 could be contained within lumen 45, wherein each line has at least one weighted object attached thereto. Additionally, weighted object 46 may have coatings 102 attached thereto to aid in the removal of cumulative matter.
  • Fig. 7 depicts yet another embodiment of a self-cleaning stent.
  • Self- cleaning stent 50 has a lumen 53 extending throughout so that fluid can pass therethrough.
  • First portion 51 and second portion 52 of self-cleaning stent 50 have an inner diameter 55 that is less than the outer diameter of weighted object 54 to secure weighted object 54 within self-cleaning stent 50.
  • prongs 56 prevent weighted object 54 from occluding inner diameter 55 located at first portion 51 or second portion 52.
  • a plurality of weighted objects can be used, including those having different sizes, shapes, and coatings from that depicted in Fig. 7.
  • Fig. 8 depicts yet another embodiment of a self-cleaning stent having side drainage ports 15. Located at first portion 61 of self-cleaning stent 60 is a connection point securing mechanisms 63 to which a helical spring 65 is connected. Spring 65 is also connected to weighted object 67. Spring is biased in the direction of first portion 61; in response to patient movement, fluid flow, and/or changes in the gravitational force, weighted object 67 will temporarily distend spring 65 causing weighted object 67 to move longitudinally within lumen 64 in the direction of second portion 62.
  • spring 65 When the patient movement, fluid flow, and/or changes in the gravitational force are no longer present, spring 65 will retract pulling weighted object 67 in the direction of first portion 61. Preferably, the spring rate is minimized and the mass of weighted object 67 is maximized so that weighted object 67 is easily moved. As weighted object 67 moves within lumen 64, weighted object 67 contacts inner surface 101 of walls 18 dislodging cumulative matter attached thereto. Additionally, weighted object 67 may have additional materials or coatings attached thereto to aid in the removal of cumulative matter.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Prostheses (AREA)
  • External Artificial Organs (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne un stent capable de résister au blocage causé par une accumulation de matière dans un fluide qui passe à travers le stent. Le stent comprend une masse se déplaçant librement, le mouvement du stent ayant tendance à déloger toute matière accumulée à l'intérieur. Le dispositif peut donc rester à l'intérieur du patient sur une période de temps prolongée avant de se boucher et d'être remplacé.
PCT/US2007/014214 2006-06-22 2007-06-18 Stent auto-nettoyant WO2007149404A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2007261513A AU2007261513B2 (en) 2006-06-22 2007-06-18 Self-cleaning stent
AT07809644T ATE522190T1 (de) 2006-06-22 2007-06-18 Selbstreinigender stent
CA2659735A CA2659735C (fr) 2006-06-22 2007-06-18 Stent auto-nettoyant
EP07809644A EP2032089B1 (fr) 2006-06-22 2007-06-18 Stent auto-nettoyant
JP2009516532A JP2009540926A (ja) 2006-06-22 2007-06-18 自浄式ステント

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81564606P 2006-06-22 2006-06-22
US60/815,646 2006-06-22

Publications (2)

Publication Number Publication Date
WO2007149404A2 true WO2007149404A2 (fr) 2007-12-27
WO2007149404A3 WO2007149404A3 (fr) 2008-02-14

Family

ID=38691679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/014214 WO2007149404A2 (fr) 2006-06-22 2007-06-18 Stent auto-nettoyant

Country Status (7)

Country Link
US (1) US8864842B2 (fr)
EP (1) EP2032089B1 (fr)
JP (1) JP2009540926A (fr)
AT (1) ATE522190T1 (fr)
AU (1) AU2007261513B2 (fr)
CA (1) CA2659735C (fr)
WO (1) WO2007149404A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2413839B1 (fr) * 2009-04-02 2014-05-07 Cook Medical Technologies LLC Système et procédé de maintien de la perméabilité d'un stent à l'aide d'un aimant

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7377939B2 (en) * 2003-11-19 2008-05-27 Synecor, Llc Highly convertible endolumenal prostheses and methods of manufacture
US20090192588A1 (en) * 2008-01-29 2009-07-30 Taeoong Medical Co., Ltd Biodegradable double stent
US20100042202A1 (en) * 2008-08-13 2010-02-18 Kamal Ramzipoor Composite stent having multi-axial flexibility
EP2961465B1 (fr) 2013-02-28 2017-05-31 Boston Scientific Scimed, Inc. Dispositifs médicaux pour utilisation le long du tractus biliaire et/ou pancréatique
US20200188147A1 (en) * 2018-12-14 2020-06-18 Drexel University Geometrically tunable hydrogel-based chemically-eluting shunt prosthesis
JP7348292B2 (ja) 2019-01-07 2023-09-20 ボストン サイエンティフィック サイムド，インコーポレイテッド 移動防止機構付ステント
EP4255356A1 (fr) 2020-12-02 2023-10-11 Boston Scientific Scimed, Inc. Endoprothèse à caractéristiques de déploiement améliorées
CN113081416A (zh) * 2021-02-25 2021-07-09 中国人民解放军北部战区总医院 泌尿系支架

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036047A1 (fr) 2000-11-01 2002-05-10 Mathur Sandip V Stent nettoyable actionne magnetiquement et procede associe

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1889705A (en) * 1931-03-16 1932-11-29 Carroll P Sherwood Flow meter
GB1165698A (en) * 1965-11-05 1969-10-01 Guinness De Laszlo M A P Henry Improvements in or relating to Prostheses
US4479796A (en) * 1982-11-15 1984-10-30 Medtronic, Inc. Self-regenerating drug administration device
US4699611A (en) * 1985-04-19 1987-10-13 C. R. Bard, Inc. Biliary stent introducer
US5782792A (en) * 1986-11-21 1998-07-21 Cypress Bioscience, Inc. Method for treatment of rheumatoid arthritis
US5240601A (en) * 1988-11-09 1993-08-31 Chembiomed, Ltd. Affinity supports for hemoperfusion
IL89297A0 (en) * 1989-02-15 1989-09-10 Technion Res & Dev Foundation Auxilary intra-urethral magnetic valve for persons suffering from urinary incontinence
US5397351A (en) * 1991-05-13 1995-03-14 Pavcnik; Dusan Prosthetic valve for percutaneous insertion
US5798697A (en) * 1991-09-24 1998-08-25 Wiseman; Brian Exhaust/supply direction indicator
US5291182A (en) * 1991-09-24 1994-03-01 Brian Wiseman Fluid flow direction detector
US5661461A (en) * 1991-09-24 1997-08-26 Wiseman; Brian Exhaust/supply direction indicator
US5217493A (en) * 1992-03-11 1993-06-08 Board Of Regents, The University Of Texas System Antibacterial coated medical implants
US5380299A (en) * 1993-08-30 1995-01-10 Med Institute, Inc. Thrombolytic treated intravascular medical device
US6774278B1 (en) * 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US7550005B2 (en) * 1995-06-07 2009-06-23 Cook Incorporated Coated implantable medical device
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
US5647843A (en) * 1996-05-24 1997-07-15 Vance Products Incorporated Anti-reflux ureteral stent
US20040068241A1 (en) * 1996-06-04 2004-04-08 Fischer Frank J. Implantable medical device
US6530951B1 (en) * 1996-10-24 2003-03-11 Cook Incorporated Silver implantable medical device
DE69732229T2 (de) * 1997-07-17 2005-12-29 Schneider (Europe) Gmbh Stent sowie Herstellungsverfahren dafür
JP2002508209A (ja) * 1997-12-15 2002-03-19 プロリフィックス メディカル， インコーポレイテッド 再狭窄の低減のための血管ステント
US6066088A (en) * 1998-07-13 2000-05-23 Phillip Davis Inventions, Inc. Intraurethral magnetic valve
US6746489B2 (en) * 1998-08-31 2004-06-08 Wilson-Cook Medical Incorporated Prosthesis having a sleeve valve
DE69913163T2 (de) * 1998-08-31 2004-09-09 Wilson-Cook Medical Inc. Antirückflussspeiseröhrenprothese
DE19948783C2 (de) * 1999-02-18 2001-06-13 Alcove Surfaces Gmbh Implantat
US20050060044A1 (en) * 1999-08-05 2005-03-17 Ed Roschak Methods and devices for maintaining patency of surgically created channels in a body organ
US7175644B2 (en) * 2001-02-14 2007-02-13 Broncus Technologies, Inc. Devices and methods for maintaining collateral channels in tissue
US6419657B1 (en) * 2000-08-22 2002-07-16 Advanced Cardiovascular Systems, Inc. Flow regulator valve to optimize stent deployment and method of using the same
EP1181977B1 (fr) * 2000-08-24 2007-12-05 Kaneka Corporation Procédé d'adsorption et d'élimination et utilisation d'un adsorbeur de cannabinoides endogènes
JP4283430B2 (ja) * 2000-09-26 2009-06-24 株式会社カネカ エンテロトキシンの吸着材、吸着除去方法および吸着器
KR20030045847A (ko) * 2000-10-31 2003-06-11 쿡 인코포레이티드 코팅된 이식형 의료 장치
US6921378B2 (en) * 2001-10-09 2005-07-26 Boston Scientific Scimed, Inc. Anti-reflux drainage devices and methods
US7993390B2 (en) * 2002-02-08 2011-08-09 Boston Scientific Scimed, Inc. Implantable or insertable medical device resistant to microbial growth and biofilm formation
JP4277113B2 (ja) * 2002-02-27 2009-06-10 大同特殊鋼株式会社 耐熱ばね用Ｎｉ基合金
EP2851097A3 (fr) * 2002-07-12 2015-06-10 Cook Medical Technologies LLC Ballons d'angioplastie revêtus d'un agent pharmaceutique
US20050008763A1 (en) * 2002-09-24 2005-01-13 Schachter Steven C. Antimicrobial coatings for medical applications
US6929664B2 (en) * 2003-12-05 2005-08-16 Fossa Medical, Inc. Open lumen stents
CA2557583A1 (fr) 2004-01-20 2005-08-11 Massachusetts General Hospital Stent de filtrage permanent de thrombus
US20060089589A1 (en) * 2004-10-21 2006-04-27 Portnoy Harold D Resistive shunt valve
WO2007127419A2 (fr) 2006-04-28 2007-11-08 The Board Of Trustees Of The Leland Stanford Junior University Système et procédé permettant de contrarier le dépôt de matière sur des dispositifs situés dans les voies urinaires
US20080269546A1 (en) * 2007-04-24 2008-10-30 David Wilkie Self-acting urethral valve

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036047A1 (fr) 2000-11-01 2002-05-10 Mathur Sandip V Stent nettoyable actionne magnetiquement et procede associe

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2413839B1 (fr) * 2009-04-02 2014-05-07 Cook Medical Technologies LLC Système et procédé de maintien de la perméabilité d'un stent à l'aide d'un aimant

Also Published As

Publication number Publication date
JP2009540926A (ja) 2009-11-26
AU2007261513B2 (en) 2013-06-13
US8864842B2 (en) 2014-10-21
EP2032089B1 (fr) 2011-08-31
US20070299506A1 (en) 2007-12-27
WO2007149404A3 (fr) 2008-02-14
EP2032089A2 (fr) 2009-03-11
CA2659735C (fr) 2012-01-24
AU2007261513A1 (en) 2007-12-27
ATE522190T1 (de) 2011-09-15
CA2659735A1 (fr) 2007-12-27

Similar Documents

Publication Publication Date Title
US8864842B2 (en) Self-cleaning stent
AU2008293471B2 (en) Medical implant having improved drug eluting features
AU2007290217B2 (en) Stent with antimicrobial drainage lumen surface
US20080051911A1 (en) Stent with antimicrobial drainage lumen surface
EP1649880B1 (fr) Implants de gestion de liquides ayant une meilleur résistance à l'occlusion
US20080086214A1 (en) Medical device having a sleeve valve with bioactive agent
JP2010534086A (ja) 血管内薬剤送達用ハイポチューブ
US20180042742A1 (en) Stent assembly and method of preparing the stent assembly
EP2413839B1 (fr) Système et procédé de maintien de la perméabilité d'un stent à l'aide d'un aimant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07809644

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2659735

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007261513

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009516532

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007809644

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007261513

Country of ref document: AU

Date of ref document: 20070618

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: RU